Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624.

Published: 17th May 2018

Authors: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al.

Conclusion

Some 1046 patients were randomized to oral Edoxaban or low molecular weight heparin (Dalteparin) for at least six months. At twelve months, recurrent venous thromboembolism was lower with Edoxaban (7.9 versus 11.3 per cent), but major bleeding rates were higher (6.9 versus 4 per cent); all non-significant.

Pubmed Link

Your comments

0 Comments